Trial: 201904129

A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-Targeting Human Antibody-Cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-Line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Phase

III

Principal Investigator

Weiss, Mia

Disease Site

Colon; Small Intestine; Soft Tissue; Stomach; Urinary Bladder

Learn more about this study at: clinicaltrials.gov